Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) (UROCOR)

AstraZeneca

Status: Completed

Conditions: Prostatic Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01284608

NIS-OES-DUM-2010/1

Details and patient eligibility

About

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Enrollment: 197 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
• Provision of informed consent prior to conducting any study-related procedure

Exclusion criteria

• Patient involved in a Clinical Trial